#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acute myeloid leukaemia (in remission) Marginal zone lymphoma recurrent Head and neck cancer Lip and/or oral cavity cancer Immunodeficiency Cutaneous calcification VEXAS syndrome Neuropathy peripheral Mixed-type liposarcoma Spina bifida Cystic fibrosis gastrointestinal disease Albright's disease Liver transplant rejection Transient ischaemic attack Adrenoleukodystrophy More trials…

    Learn about Rare Diseases

    Progressive supranuclear palsy – Diagnostics Acute respiratory distress syndrome – Life with Disease Hereditary motor and sensory neuropathy – Basic Information Factor VIII deficiency – Basic Information Noonan syndrome – Treatment Activated PI3 kinase delta syndrome – Trials in Disease Pelizaeus-Merzbacher disease – Basic Information Synovial sarcoma – Trials in Disease Atypical haemolytic uraemic syndrome – Trials in Disease Propionic acidaemia – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Clemastine Fumarate GSKVX000000034794 L-LEUCINE [18F]CPFPX Regn7075 ULEFNERSEN Relugolix Capivasertib Nalbuphine Hydrochloride Bi 3720931 Pertuzumab Hexaminolevulinate Ion440 Propylene Glycol Crisantaspase Ly3437943 Sodium Oregovomab Insulin Icodec Givinostat Elivaldogene Autotemcel More therapies…

    Learn about Your Condition

    Renal cell carcinoma Ankylosing spondylitis Primary hyperoxaluria Lymphocytic leukaemia Limb reduction defect Stomatitis Nasopharyngeal cancer Biliary adenoma Loeys-Dietz syndrome Craniotomy Asymptomatic HIV infection Autism spectrum disorder Device related infection Acute myocardial infarction MELAS syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Ustredni Vojenska Nemocnice Vojenska Fakultni Nemocnice…

Ustredni Vojenska Nemocnice Vojenska Fakultni Nemocnice Praha

U Vupvsxpu Ncqnhvwxh 1emwp Pvmudxh 1ya 0wg Crojvxi

Want to learn more about this study or check if you can participate? Contact us.

  • RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

    Recruiting

    3 1
    Czechia France Germany Hungary Italy Poland +2

  • Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ranibizumab
    Austria Belgium Bulgaria Croatia Czechia France +7

  • Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Age-related macular degeneration
    • Neovascular age-related macular degeneration
    Investigated Drugs:
    • Ranibizumab
    Austria Czechia Denmark France Germany Greece +3

  • Study on Fluid Management to Reduce Post-Surgery Complications in Brain Surgery Patients Using Magnesium Chloride, Potassium Chloride, and Sodium Chloride

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Magnesium Chloride Hexahydrate
    • Sodium Acetate Trihydrate
    • Potassium Chloride
    Czechia

  • A Study of Darovasertib Before Surgery or Radiation Therapy for Patients with Early-Stage Uveal Melanoma That Has Not Spread

    Recruiting

    3 1 1
    Investigated Diseases:
    • Uveal melanoma
    Investigated Drugs:
    • Darovasertib
    Austria Belgium Czechia Denmark France Germany +4

  • Long‑Term Follow‑Up Study of Belzupacap Sarotalocan in Patients with Early Choroidal Melanoma

    Not yet recruiting

    3 1
    Investigated Drugs:
    • Belzupacap Sarotalocan
    Austria Belgium Czechia France Germany Italy +2

  • Study on Empagliflozin for Patients with Non-Alcoholic Steatohepatitis (NASH)

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Metabolic dysfunction-associated steatohepatitis
    Investigated Drugs:
    • Empagliflozin
    Czechia

  • Study on the Effects of Ponsegromab on Quality of Life and Safety in Adults with Heart Failure

    Not recruiting

    2 1
    Investigated Drugs:
    • Ponsegromab
    Czechia Germany Hungary Poland Spain

  • Study on the Effectiveness and Safety of Belzupacap Sarotalocan for Patients with Small Choroidal Melanoma or Indeterminate Lesions

    Not recruiting

    3 1
    Investigated Drugs:
    • Belzupacap Sarotalocan
    Austria Belgium Czechia Denmark France Germany +6

  • Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

    Not recruiting

    3 1
    Investigated Drugs:
    • Asundexian
    Austria Belgium Bulgaria Czechia Denmark Finland +14
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!